Pfizer said that Litfulo (ritlecitinib) is the first alopecia areata therapy to be cleared for use in adolescents in the EU. JAK1/2 inhibitor Olumiant (baricitinib) was the first drug to be ...

Pfizer’s JAK/TEC inhibitor Litfulo has been ... Given as a once-daily tablet, Litfulo (ritlecitinib) has been recommended by cost-effectiveness agency NICE for use in people aged 12 and over.

Ritlecitinib, a kinase inhibitor ... Some of the major players include, Pfizer, Follicum AB, Eli Lilly and Company/Incyte Corporation, Concert Pharmaceuticals, TechnoDerma Medicines, and others. These ...

Group alleged bias toward white, Asian-American applicants Pfizer expresses pride in its commitment to diversity Jan 31 (Reuters) - Pfizer (PFE.N), opens new tab has resolved a lawsuit by a ...

Pfizer Ltd. key Products/Revenue Segments include Pharmaceuticals, Sale of services, Scrap for the year ending 31-Mar-2024.For the quarter ended 31-12-2024, the company has reported a Standalone Total ...

After hours: 31 January at 7:59:49 pm GMT-5 ...

IBD (inflammatory bowel disease) is a chronic inflammatory disease of the gastrointestinal tract with increasing incidence worldwide. Multiple factors, such as genetic background, environmental and ...